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ABSTRACT
The Epstein–Barr virus (EBV) is an oncogenic human
Herpes virus found in 15% of diffuse large B-cell
lymphoma (DLBCL). EBV encodes miRNAs and
induces changes in the cellular miRNA profile of
infected cells. MiRNAs are small, non-coding RNAs
of 19–26nt which suppress protein synthesis by
inducing translational arrest or mRNA degradation.
Here, we report a comprehensive miRNA-profiling
study and show that hsa-miR-424, -223, -199a-3p,
-199a-5p, -27b, -378, -26b, -23a, -23b were
upregulated and hsa-miR-155, -20b, -221, -151-3p,
-222, -29b/c, -106a were downregulated more than
2-fold due to EBV-infection of DLBCL. All known
EBV miRNAs with the exception of the BHRF1
cluster as well as EBV-miR-BART15 and -20 were
present. A computational analysis indicated poten-
tial targets such as c-MYB, LATS2, c-SKI and SIAH1.
We show that c-MYB is targeted by miR-155 and
miR-424, that the tumor suppressor SIAH1 is
targeted by miR-424, and that c-SKI is potentially
regulated by miR-155. Downregulation of SIAH1
protein in DLBCL was demonstrated by immuno-
histochemistry. The inhibition of SIAH1 is in line
with the notion that EBV impedes various
pro-apoptotic pathways during tumorigenesis.
The down-modulation of the oncogenic c-MYB
protein, although counter-intuitive, might be ex-
plained by its tight regulation in developmental
processes.
INTRODUCTION
The Epstein–Barr virus (EBV) asymptomatically infects
>95% of the adult population world wide, but sporadic-
ally induces infectious mononucleosis. In the vast majority
of cases, the virus establishes a lifelong latent infection
without further complications. Under certain circum-
stances, however, the virus has oncogenic potential
in vivo which is reﬂected by its ability to growth-transform
B-lymphocytes in vitro (1). It is associated with not only
tumors of B-cell origin such as Burkitt’s and Hodgkin’s
lymphoma, but also carcinomas of the stomach and the
oropharyngeal cavity (nasopharyngeal carcinoma). EBV is
present in virtually all cases of peripheral NK- and T-cell
lymphoma and can be detected in 15% of diffuse large
B-cell lymphoma (DLBCL) [for a recent review, see (2)].
In tumor cells, EBV expresses a limited set of so-called
latent proteins as well as the highly transcribed
non-protein encoding EBER RNAs. EBV encodes a set
of 25 miRNAs that are also found in EBV-positive tumors
(3–5). Furthermore, an EBV-encoded small nucleolar
RNA (snoRNA) was previously discovered (6).
MiRNAs are short, 19–26 nt RNAs with partial
homology to sequences in their target mRNAs. Loading
of miRNA to the 30-untranslated region (30UTR) of its
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target mRNA by RNA-induced-silencing-complex (RISC)
results in either translational repression or mRNA degrad-
ation ultimately leading to reduced protein synthesis [for
review, see (7–10)]. In addition to its own non-coding
RNAs, EBV induces cellular non-coding RNAs
(ncRNAs) such as vault RNA (11) and cellular miRNAs
(12). Conversely, EBV infection represses several cellular
miRNAs (5). The aim of this study was to establish the
cellular and viral miRNA proﬁle of DLBCL and to
identify and analyze potential targets for the deregulated
miRNAs.
MATERIAL AND METHODS
Patients tissue and immunohistochemistry
Freshly snap frozen B-cell lymphoma tissue samples used
for miRNA expression analysis and qRT-PCR were
retrieved from the ﬁles of the Institute for Surgical
Pathology, University Hospital, Zu¨rich, Switzerland.
Diagnosis was done on formalin ﬁxed, parafﬁn
embedded tissue of the corresponding patient according
to the WHO-classiﬁcation system by two pathologists
(TR and MT). The study was approved by the local
Ethical Committee. Immunohistochemical staining was
conducted on parafﬁn-embedded sections by an auto-
mated staining system (Discovery Ventana Medical
System, Tucson, AZ) using Ventana ultraViewTM
Universal DAB Detection Kit with the commercially
available antibody anti-SIAH1 (Novus Biologicals,
catalog number: H00006477-M01A, Clone: 2F2, dilution
1:100). Antigen-retrieval was performed with a
TRIS-based buffer for 90min at 98C.
Cell lines and constructs
HEK 293-T, U2932 and their EBV positive derivatives
where cultivated at 37C, 5% CO2 in RPMI 1640
GlutaMaxTM medium supplemented with 10% fetal
bovine serum (Invitrogen, Carlsbad, USA) and 1x
Antibiotics/Antimycotics (Sigma, St. Louis, USA).
Additionnaly, EBV-GFP virus infected U2932 cells were
maintained under selective pressure of G418 (200mg/ml,
Invitrogen). The dual luciferase reporter plasmid
pMIR-RL has been described elsewhere (5). 30UTR frag-
ments of c-MYB (accession number: NM_005375; SIAH1
(accession number: NM_003031), c-SKI (Accession
number: NM_003036.3) and LATS2 (Accession number:
NM_014572) mRNA were cloned via PCR ampliﬁcation
from testis cDNA and ligated into the corresponding SacI
and SpeI sites of pMIR-RL. PCR products of genomic
DNA containing hsa-miR-424 precursor sequences
ﬂanked by 100 bp were cloned into eukaryotic expres-
sion vector pSG5 (Stratagene, La Jolla, USA) using
EcoRI and BglII restriction sites. Respective miRNA ex-
pression was conﬁrmed separately by northern blotting.
MiR-expression vector pSG5-miR-155 was described pre-
viously (13).
Small RNA cloning
Small RNA cloning was carried out by Vertis
Biotechnology (Weihenstephan, Germany) and has been
described earlier (5). The small RNA fraction from each
four available lymphoma and normal tissues was isolated
using miRVana-microRNA isolation kit (Ambion,
Austin, USA). RNA was run on 12.5% polycrylamide
gel and stained with SYBRgreenII. Fraction from 15 to
40 nt was re-eluted and dissolved in water. Further on,
small RNAs were poly(A)-tailed using poly(A) polymer-
ase, and an adaptor was ligated to the 50 phosphate of the
miRNAs: (50 end adaptor, 30 nucleotides: 50-GCCTCCCT
CGCGCCATCAGCTNNNNGACCTTGGCTGTCACT
CA-30). NNNN represents a ‘barcode’ sequence. Next,
ﬁrst-strand-cDNA synthesis was performed using an
oligo(dT)- linker primer and M-MLV-RNaseH reverse
transcriptase (30 end oligo dT linker primer; 61 bases:
50-GCCTTGCCAGCCCGCTCAGACGAGACATCGC
CCCG C(T)25-30). The resulting cDNAs were PCR
ampliﬁed in 22 cycles using the high-ﬁdelity Phusion poly-
merase (Finnzymes, Espoo, Finland). The 120–135-bp
ampliﬁcation products were conﬁrmed by polyacrylamide
gel electrophoresis (PAGE) analysis. Both cDNAs pools
were mixed in equal amounts and subjected to gel frac-
tionation. The 120–135-bp fraction was electroeluted from
6% PAA-gels. After isolation with Nucleospin Extract II
(Macherey and Nagel, Bethlehem, USA), cDNA pools
were dissolved in 5mM Tris–HCl (pH 8.5) with a concen-
tration of 10 ng/ml and used in single-molecule
sequencing. Massively parallel sequencing was performed
by 454 Life Sciences (Branford, USA) using the Genome
Sequencer 20 system.
Sequence annotation
The adapter sequences and poly(A) tails were removed
from the sequences. The remaining sequences of length
15 bases or longer were subjected to later analysis. Due
to the disturbing signal from poly(A) tails in 454
sequencing, the sequences were analyzed semi-manually,
distinguishing the false ‘A’ signals in the sequences. The
set of sequences were ﬁrst compared with the mature se-
quences of known miRNAs from miRBase v12.0. The se-
quences that are not perfectly matching may be artifacts of
the cloning procedure or a result of non-templated modi-
ﬁcation of mature miRNAs and were annotated according
to the best blast hit to the database. The rest of the se-
quences were again compared with the hairpin sequences
of known miRNAs from miRBase v12.0, and the star se-
quences of known miRNAs that have not been annotated
in the database were identiﬁed. Remaining reads were
blasted against non-coding RNA databases including
rRNA, tRNA, snoRNA, etc., retrieved from Genbank
(http://www.ncbi.nlm.nih.gov/Genbank/), snoRNABase
(http://www-snorna.biotoul.fr/) and fRNAdb (http://
www.ncrna.org/frnadb/blast). The annotated sequences
were discarded from the sequence set. The non-coding
RNA sequences from EBV were identiﬁed by the blast
against EBV genome retrieved from Genbank (Acc. No.:
AJ507799). Remaining sequences were subjected to
miRDeep (14) algorithm for searching of novel miRNAs.
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Differential expression detection
Relative expression level changes was calculated by
counting the numbers of respective miRNA reads
normalized to the total number of annotated miRNAs
in percent. Ratio of resulting abundance in library (or
cloning frequency) was calculated between normal tissue
control (tonsil) and respective lymphoma entity giving
relative expression level change. Potentially interesting
miRNA candidates where chosen according to the
criteria of a 2-fold expression level change and
>50 reads within one of the examined library. After ex-
tracting all known miRNA and other non-coding RNA
sequences from the two libraries we applied mirDeep al-
gorithm (14) to the remaining reads. The EBV genome
sequence (Accession number: AJ507799) was included to
a modiﬁed miRDeep search.
In silico target prediction
Selected miRNA candidates where checked by to up to
ﬁve different available target prediction algorithms
(PicTar 4.1 (http://pictar.bio.nyu.edu/cgi-bin/PicTar_ver-
tebrate.cgi), mirbase (http://microrna.sanger.ac.uk/
targets/v5/), TargetScan (http://www.targetscan.org/),
miRTar (http://mirtar.mbc.nctu.edu.tw/) and miRNA
viewer (http://cbio.mskcc.org/cgi-bin/miRNAviewer/
miRNAviewer.pl). For each miRNA candidate, very strin-
gent conditions where set in search for overlapping target
predictions (genes were only considered as possible targets
if one less than the given algorithms resulted in common
predictions). To further narrow the amount of potential
target genes the resulting list was aligned to their known
relevance to lymphomagenesis by a PubMed search.
Reverse transcription and semi-quantitative RT–PCR
Tissue samples where homogenized under RNAse-free
conditions and total RNA was isolated by standard
TRIzol reagent (Invitrogen, Carlsbad, USA) according
to the manufacture’s recommendations. DNAseI
(Invitrogen, Carlsbad, USA) treated RNA was
poly-Adenylated using Ambion’s (Austin, USA)
poly(A)-tailing Kit followed by chloroform-phenol puriﬁ-
cation. Reverse transcription reaction was carried out by
application of SuperScriptTM III First strand synthesis
system (Invitrogen, Carlsbad, USA) using a poly(T)
adapter primer (50-GCGAGCACAGAATTAATACGA
CTCACTATAGG(T)12VN*-3
0). Semi-quantitative RT–
PCR was done as described previously (15) on
Light-Cycler 1.5 System using LightCycler FastStart
DNAMasterPLUS SYBR Green I Kit (Roche Applied
Science, Mannheim, Germany). The primers used are:
Reverse primer (50-GAGCACAGAATTAATACGAC-30)
miR-speciﬁc forward primers (miR-424: 50-CAGCAGCA
ATTCATGTTTTGAA-30; miR-155: 50-TTAATGCTA
ATCG TGATAGGGGTAA-30). Human 5.8s rRNA was
used for internal normalization (primer: 50-CTACGCCT
GTCTGAGCGTCGCTT-30). Following programs were
established for quantitative PCR: (i) initial denaturation
10min 95, denaturation 10 s, annealing 63C 5 s, ampli-
ﬁcation 72C 5 s for miR-155; (ii) initial denaturation
5min 95C, denaturation 10 s, annealing 66C 5 s, ampli-
ﬁcation 72C 5 s for 5.8 s rRNA; (iii) initial denaturation
5min 95C, denaturation 10 s, annealing from 68C to
61C (touch-down step starting with cycle 10, decrease
of 1/cycle) 5 s, ampliﬁcation 72C 5 s for miR-424.
Cycle number was adjusted individually for each
miRNA according to their expression level. Relative ex-
pression level changes were calculated according to
2(cT
)-method as described previously (16).
Transfection and luciferase assay
Plasmid transfections for luciferase assays were performed
with 165 ng pMIR-RL, 333 ng pSG5 per 1 105 cells in a
24-well plate using FugeneHD reagent (Roche Applied
Science, Mannheim, Germany) as described by the manu-
facturer’s instructions. Luciferase activity was measured
48-h post-transfection using dual-glo luciferase reporter
system as described by the manufacturer’s instructions
(Promega, San Luis Obispo, USA). Luciferase activity
was measured on Wallac Victor2 (Perkin-Elmer,
Waltham, USA) multiplate reader in LUIMITRACTM
96-well plates (Greiner Bio-one, Frickenhausen,
Germany).
Northern blot
Total RNA was extracted from cells using TriZol Reagent
(Invitrogen, Carlsbad) following the vendor’s recommen-
dations. Total RNA measuring 25 mg was routinely
electrophoresed through 12% urea-polyacrylamide gel
and then electroblot-transferred to nylon membrane
Hybond XL (Amersham) for 1 h at 2mA/cm2. The
membrane was EDC chemically cross-linked as described
(17). Blots were hybridized with radioactive-labeled anti-
sense probe overnight and then washed twice for 15min
with 5 SSC, 1% SDS and twice for 15min with 1SSC,
1% SDS. As radioactive probes, we used RNA probes
labeled with miRVana Probe construction kit (Ambion)
according to the manufacturer’s instructions. The follow-
ing antisense probes were used: miR-424: 50-UUC AAA
ACA UGA AUU GCU GCU G-30, miR-155: 50-CCC
CUA UCA CGA UUA GCA UUA A-30.
MicroRNA blocking assay and western blot
MicroRNA blocking was done by transfecting 0.75 nMol
per 106 cells miR-155 or miR-424 inhibitors or respective
miRNA mimics (Ambion). Used cells were U2932 and
EBV infected subclones transfected with lipid based
siPORTTM NeoFXTM Transfection Agent (Ambion) ac-
cording to manufactures recommendation. Anti-miRTM
miRNA Inhibitors—Negative Control #1 (Ambion)
served as mock transfectant. Transfection efﬁcacy was
assessed by using a FAM-labeled Oligonucleotide
(Ambion). After transfection procedure cells were
cultivated for 3 days, counted and protein extracts were
created by adding 5 sample buffer (Promega). Protein
levels were normalized according to the counted cell
number. Western blot was performed as previously (18).
In brief, after electrophoresis proteins were transferred
onto Nitrocellulose membranes, blocked in 2.5%
PBS-milk powder. Anti-c-MYB Antibody (Upstate,
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mouse clone 1-1) was diluted 1:500, anti-SIAH1 1:250
(Novus Biological, mouse clone 2F2) and anti-b-catenin
(Cell signaling) 1:1000 in 1% PBS-milk powder an
incubated for 1 h at room temperature. Rabbit anti–bactin
(Cell signaling; 1:1000 in 0.5% PBS/BSA) detection served
as a loading control. After three times each 10min
washing in 0.1% PBS/Tween secondary anti-mouse
peroxidase-antibody (Biorad) was diluted 1:1000 in 2.5%
PBS-milk powder or peroxidase-anti rabbit IgG
(Sigma-Aldrich) 1:20 000 and incubated for 45min at
room temperature. After additional washing steps
proteins were detected using ECL chemiluminescence kit
(GE Healthcare) and visualized on X-ray ﬁlms.
Immunohistochemistry
Immunohistochemical staining was conducted on
parafﬁn-embedded sections by an automated staining
system (Discovery Ventana Medical System, Tucson,
AZ) using Ventana ultraViewTM Universal DAB
Detection Kit with the commercially available antibody
anti-SIAH1 (Novus Biologicals, catalog number:
H00006477-M01A, Clone: 2F2, dilution 1:100).
Antigen-retrieval was performed with a TRIS-based
buffer for 90min at 98C.
Statistical analysis
Densitometric quantiﬁcation for northern blot was done
by using ImageQuant software (Molecular Dynamics,
GE-Healthcare, USA). Statistical analysis of the
Luciferase-Assay and quantitative RT–PCR was per-
formed with GraphPad Prism 4.0 (Graph Pad software,
La Jolla, CA, USA).
RESULTS
Small RNA library annotation
To generate miRNA cDNA libraries, tissue samples of
four EBV-positive and four EBV-negative DLBCLs
were pooled. The presence or absence of EBV in the
tissues was determined by EBER in situ hybridization.
All of the EBV-positive DLBCLs exhibited an EBV
latency type I (EBER+/EBNA1+/LMP1-/EBNA2-/
BZLF1-). Characteristics of the used tissues are shown in
Supplementary Table S1. Library annotation resulting
from 454 sequencing was done semi-manually as described
before (5). In the library of EBV-negative DLBCL, 56%
of a total of 97 182 reads represented known miRNA
sequences, while 37% of a total of 85 221 reads were
miRNA derived in the EBV-positive DLBCL library.
Figure 1A shows the distribution of miRNA and
other small ncRNA sequences in the two libraries as
indicated. The number of unidentiﬁed sequences ranged
between 10–13%. We also monitored the sequence count
distribution of all expressed miRNAs in the two tumor
entities. Sequence counts covered a range of ﬁve orders of
magnitude (Figure 1B). The majority (>50%) of cellular
miRNA species where present at very low level (1–10)
reads, while only 11–19% were abundantly expressed
(100–1000 reads). Of note, miR-16 accounted for 19.6%
of all reads in the EBV-negative and for 14.7% of all
reads in the EBV-positive DLBCL.
The advantage of miRNA cloning and sequencing is the
potential identiﬁcation of so far unknown miRNAs. We
found six different candidate sequences matching the
human genome and ﬁtting mirDeep algorithm miRNA
prediction criteria (14). Of these, ﬁve sequences were
described in the Sanger Database while this analysis was
under way (data not shown). A sixth sequence (ACAUAC
UUCUUUAUAUGCCCAU) homologous to
hsa-miR-1-2* was found four times but could not be
veriﬁed by northern blotting in the uninfected DLBCL
line U2932, or the EBV-infected derivatives thereof. This
potential miRNA was not pursued further.
Analysis of EBV-encoded miRNA expression
In the library derived from EBV-positive DLBCL,
virus-encoded miRNAs represented 1.7% of all identiﬁed
miRNA reads (Figure 1A). We found the strongest expres-
sion for EBV-miR-BART7 and -BART22 (14.9% each), -
BART10 (9.6%), -BART11-5p (8.6%) and -BART16
(7.3%), where 100% is considered as the total number
of EBV miRNA reads in the library. The DLBCL
samples contained the previously described
EBV-encoded miR-BART21 and -BART22 (5). The dis-
tribution of the various EBV-miRNAs is graphically
shown in Figure 2A and listed in Supplementary
Table S2. In the EBV-positive tumors, we found all
known EBV-encoded miRNAs with the exception of
those encoded by the BHRF1 cluster and also no reads
from EBV-miR-BART15 and -BART20. This is in line
with our previous data for EBV-positive NPC (5) and a
report about viral miRNA expression in EBV-infected
gastric carcinoma (19) where the BHRF1-derived
miRNAs were also not present.
MicroRNA expression pattern in EBV-positive
versus -negative DLBCL
We then compared the cellular miRNA expression levels
in the EBV-positive versus -negative DLBCLs. We set an
abundance threshold of >50 reads (corresponding to
0.05% of all reads) in one of the examined libraries
and an expression level change of 2-fold. This resulted
in a distinct miRNA proﬁle characteristic for
EBV-positive DLBCLs. Nine miRNAs (hsa-miR-424,
-223, -199a-3p, -199a-5p, -27b, -378, -26b, -23a, -23b)
were found to be upregulated and seven miRNAs
(hsa-miR-155, -20b, -221, -151-3p, -222, -29b/c, -106a)
were downregulated as shown in Figure 2B and 2C, re-
spectively. Some of the deregulated miRNAs had already
been linked to cancer (Table 1). Clustered miRNAs
(miR-27b/miR-23b; miR-221/miR-222; miR-20b/
miR-106b) exhibited similar expression changes suggest-
ing not only co-transcription, but also co-processing
events. The results of the sequence analysis are
summarized in Supplementary Table S3.
MicroRNA candidate expression validation by RT–PCR
It was previously shown that miR-155 is strongly
upregulated in human B-cell lymphomas (20) and that
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miR-155 has the properties of an oncogene (21). We
had found that miR-155 is also strongly upregulated in
NPC as compared to normal control tissue (5); in
addition, EBV-infection of BL cell lines resulted in dra-
matically increased amounts of this miRNA (12). In
contrast, here we found a relative decrease of miR-155
expression in the EBV-positive as compared to the
EBV-negative DLBCLs (3.5% versus 15.3% representa-
tion, respectively; see Figure 2C and Supplementary
Table S3. To analyze this in more detail, we
extracted RNA from snap-frozen tumor tissues (10 lymph-
omas from EBV-negative and eight from EBV-positive
tissues) and measured miRNA levels by qRT-PCR in com-
parison to RNA extracted from non-transformed ton-
sillar tissue. The value obtained from this latter tissue
was set to 1. As shown in Figure 3A, the relative
levels of miR-155 in the EBV-positive and -negative
DLBCL tissue were approximately the same by this
method, but were still much higher than in the tonsil
control tissue.
In addition to miR-155 which is a known oncogene, we
focused our further experiments on miR-424 which was
found in a feed-back circuit with PU.1 (22), a key tran-
scription factor employed by EBNA2-mediated trans-
formation of B-cells (23). We also compared miR-424
levels by qRT-PCR analysis because miR-424 showed
the strongest relative expression increase in EBV-positive
DLBCL versus EBV-negative DLBCL (0.94% versus
0.25%, respectively). As depicted in Figure 3A, we
found an 5-fold increase (P=0.0430) in miR-424 in
the EBV-positive cases of DLBCL. In contrast to
miR-155, which was elevated in the tumor versus
non-tumor tissue, we did not observe a statistically signiﬁ-
cant increase in miR-424 levels in EBV-negative DLBCL
as compared to the tonsil tissue but a strong upregulation
in the EBV-positive versus -negative cases.
A
B
Figure 1. Overview of small RNA and miRNA gene expression in primary B-cell lymphoma tissues obtained by deep sequencing of miRNA cDNA
libraries. (A) Proportions of various classes of small RNAs detected by sequencing of EBV-negative DLBCL (total reads: 97 182) and EBV-positive
DLBCL (total reads: 85 221) libraries as indicated. ScaRNA, small cajal body RNA; snRNA, small nuclear RNA; snoRNA, small nucleolar RNA;
rRNA, ribosomal RNA; tRNA, transfer RNA; RNP-associated, ribonucleo-protein complex derived RNAs; unknown, derived from unannotated/
intergenic regions or sequencing artefacts. (B) Distribution of miRNA genes expressed according to their sequence counts in EBV-positive and
-negative DLBCL. Shown are the numbers of unique miRNA genes plotted as a function of their expression levels as deﬁned by a given range of
sequence counts in the respective libraries of small RNAs.
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The relative up- or down-regulation of various miRNAs
was further analyzed by northern blotting using the U6
snRNA as a standard. We conﬁrmed the upregulation of
miRNAs miR-424, -223, -199a-3p, -27b, -26b and -23a,
and the downregulation of miR-155, -221 and -222 while
miR-20b and miR-106 (downregulated by sequencing)
were found upregulated by northern blotting. The quan-
tiﬁcation of the northern blots is shown in Supplementary
Table S4; the northern blots are shown in Supplementary
Figure S1A–C. We assume that the different methods
applied were responsible for these discrepancies.
However, the up- or downregulation was conﬁrmed in
the majority of miRNAs analyzed.
The levels of miR-155 and miR-424 were then analyzed
in the EBV-negative U2932 DLBCL cell line and ﬁve
EBV-convertants thereof. As shown in Figure 3B,
EBV-infection increased the amounts of the two
miRNAs to a varying degree. The clones all expressed
detectable amounts of LMP1; clones clA and cl1 which
contain no or only minute amounts of EBNA2 did also
contain elevated levels of both miR-155 and miR-424. We
had found in other experiments that the expression of
EBV BART-miRNA cluster 1
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Figure 2. miRNA expression in primary DLBCL tissue detected by 454 deep sequencing. (A) Distribution of EBV-encoded miRNAs in EBV-positive
DLBCL. The total count of EBV-derived miRNAs was set to 100%. No reads were obtained for ebv-miR-BHRF1-1, -2, -3 and ebv-miR-BART-15
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EBNA2 alone, neither in U2932 DLBCL cells (P. Trivedi,
unpublished data) nor in DG75 cells (F. Gra¨sser, unpub-
lished data), induced these microRNAs. We then looked
at qRT-PCR results in 11 EBER-positive DLBCLs. Of
these, ﬁve were LMP1-positive (latency II or III). Out of
these LMP1-positive lymphomas three patients were
immuncompromised. Interestingly, we observed a 4-fold
increase of miR-155 and a 7-fold, but statistically not
signiﬁcant increase of miR-424 expression in the
LMP1-positive lymphomas compared to the LMP1-
negative ones. There was a trend towards the upregulation
of miR-155 (P=0.0639) when we compared LMP1-
negative lymphomas with LMP1-positive DLBCLs
(Supplementary Figure S2). Taken together, our data
indicate an upregulation of miR-155 in DLBCL cell
lines and in primary lymphoma tissue, all displaying
EBV latency II or III, suggesting a role for LMP1.
In silico miRNA target prediction
We used PicTar, MirTar and TargetScan miRNA target
prediction algorithms to select a potential set of genes that
might be regulated by miR-155 and miR-424. The data
were combined to obtain overlapping results in order to
achieve a high-signiﬁcance level. We initially obtained a
list of 126 genes for miR-155 and of 27 genes for miR-424.
The predictions were further narrowed down by the
known relation of the targets to EBV biology and/or
lymphomagenesis. We ﬁnally arrived at a list of eight po-
tential miRNA target genes for miR-155 as shown in
Supplementary Figure S3. The mRNA of the AID
(activation-induced cytidine deaminase) gene was already
shown by others to be a target for miR-155 (24,25). The
same approach for miR-424 narrowed the targets down to
ﬁve candidates. C-MYB was predicted to be a target of
both miR-424 and miR-155.
Deregulated miR-424 inhibits SIAH1, miR-155/miR-424
inhibit c-MYB and miR-155 targets the c-SKI-30UTR
We chose to analyze the effects of miR-424 and miR-155
on the 30UTRs of c-MYB, SIAH1, c-SKI and LATS2. The
predicted binding sites for these are shown in Figure 4.
Two binding sites each for miR-424 and miR-155 were
predicted for the c-MYB 30UTR which was therefore
likely to be a target that deserved to be analyzed.
SIAH1, c-SKI and LATS2 had one potential binding
site. We wanted to analyze SIAH1 because a potential
link to b-catenin regulation by LMP1 via SIAH1 was sug-
gested previously (26). The 30UTRs of the four genes were
cloned into a luciferase reporter (5) construct and
co-transfected into HEK 293-T cells with the appropriate
miRNA expression vector. The expression of miR-424
from the vector pSG5 was veriﬁed by northern blotting
as shown in Supplementary Figure S4. The expression of
miR-155 from pSG5-miR-155 was described previously
(13). We observed a signiﬁcant decrease (P=0.002) of
luciferase activity for c-MYB with miR-155 by 60%
(Figure 5A). We then mutated the two predicted binding
sites for miR-155 either individually or in combination.
Surprisingly, the construct lost its responsiveness when
the miR-155 binding sites were mutated individually or
in combination (Figure 5A). This result suggested that
the two candidate miR-155-binding sites are functional
and that they apparently cooperate. This issue was not
pursued further.
We next assayed the c-MYB-luciferase construct which
contained the two miR-424 candidate binding sites and
found a reduction of 60% (P=0.0373) when miR-424
was co-expressed; here, the mutation of the potential distal
binding site (denoted 2853 in Figure 4) lost the responsive-
ness to miR-424 (P=0.0235), while mutation of the po-
tential proximal binding site (denoted 2695 in Figure 4)
had no effect indicating that only the distal candidate
binding site was functional (Figure 5B).
In a further set of experiments, miR-424 reduced the
activity of the SIAH1-30UTR reporter by 30% which
is statistically signiﬁcant (P=0.0374), and the mutation
of the predicted binding site resulted in a loss of respon-
siveness to miR-424 whilst the LATS2-30UTR was not
inﬂuenced by miR-424 (Figure 5C). Control transfections
with irrelevant miRNAs did also have no effect on the
activity of the analyzed 30UTR constructs (data not
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Figure 3. miR-155 and -424 expression validation in primary DLBCL
and DLBCL cell lines. (A) MiR-155 and miR-424 expression validation
by quantitative RT–PCR. Total RNA was extracted from three tonsil
tissues, and each 10 EBV positive and eight negative DLBCL (including
tissues previously used for small RNA-library generation), were used
for qRT-PCR analysis. Bars indicate relative expression levels
compared to normal control. *P-vlaue < 0.05, student’s t-test, paired.
(B) miR-155 and -424 expression validation by northern blot in
DLBCL cell lines. Total RNA of U2932 cell line and EBV-positive
clones (A, B, 1, 2 and 3) was detected using miRNA-speciﬁc probes
and quantiﬁed by densitometric analysis. Given numbers display
relative expression levels compared to loading control U6 snRNA.
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shown). Finally, the 30UTR of c-SKI, when assayed with
miR-155 showed a clear downregulation (P=0.0057).
After the mutation of the candidate binding site,
the c-SKI-30UTR lost its responsiveness demonstrating
that the target site is functional. This is shown in
Figure 5D.
Blocking of miR-155 and miR-424 expression leads to
higher protein level of c-MYB and SIAH1 in vivo
Next, we measured c-MYB and SIAH1 protein levels in
the presence or absence of miR-155 and miR-424 inhibitor
(Figure 6A). Transfection efﬁciency was 86–88%
(Supplementary Figure S5). Endogenous c-MYB protein
level was increased when miR-155 was inhibited in all the
clones of the EBV-positive U2932 DLBCL line compared
to scrambled control oligonucleotide. Likewise, antisense
to miR-424 increased c-MYB and SIAH1 protein levels in
these cells (Figure 6A). Downregulation of miR-155 and
miR-424 was demonstrated by northern blotting
(Supplementary Figure S6). In summary, c-MYB is nega-
tively regulated by both miR-155 and -424, while SIAH1 is
down-modulated by miR-424 and c-SKI is potentially
downregulated by miR-155.
Impact of EBV-altered miR-424 on the b-catenin/wnt
signaling pathway
SIAH1 is an E3-ubiquitin ligase that, besides multiple
other functions, is involved in regulating the b-catenin
pathway and is assumed to function as a tumor suppressor
(27). In a previous report, it was shown that the
EBV-encoded oncogene LMP1 upregulates b-catenin
through inhibition of SIAH1 expression (26). Moreover,
a recent report demonstrated that SIAH1 downregulates
b-catenin by direct ubiquitinylation (28). To gain further
insight into the functional relevance of miR-424
over-expression in the EBV-positive DLBCL, we assayed
the levels of b-catenin upon inhibition of SIAH1. As
shown in Figure 6A, inhibition of miR-424 clearly leads
to increased levels of SIAH1 demonstrating a direct link
between this miRNA and SIAH1. This protein blot
conﬁrms the experiments that showed a downregulation
of the SIAH1-30UTR by miR-424 (Figure 5C). This ob-
servation is conﬁrmed in primary lymphoma tissue where
SIAH1 protein expression demonstrated by immunohisto-
chemistry appears to be downregulated in EBV+ versus
EBV- DLBCLs (Figure 6B). Conversely, we can clearly
show an upregulation of b-catenin after ectopic expression
of miR-424 in two out of three different EBV+subclones
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of the U2932 cell line (Figure 6C). So far, a deregulation
of b-catenin has not been shown directly in DLBCL,
however, overexpression of b-catenin has been found in
cutaneous B-cell lymphomas (29).
DISCUSSION
This is the second report aimed at elucidating the miRNA
proﬁle of tumors infected by EBV using a deep-sequencing
approach. In a ﬁrst report, we had compared the miRNA
levels in endemic nasopharyngeal carcinoma (NPC) to
non-infected, healthy control tissue (5). In NPC, we
detected two novel EBV microRNAs designated
ebv-miR-BART21 and -BART22 that were both present
in DLBCL samples analyzed here pointing at a role for
these miRNAs in EBV-driven tumor transformation.
Furthermore, we did not detect ebv-mir-BART15 and
-BART20 as observed in NPC where we found no or
only one read for -BART15 and -BART20 (5). Of the
EBV miRNAs, the strongest expression was observed
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Figure 5. Luciferase reporter assays. Fireﬂy luciferase reporters fused to the c-MYB, SIAH1, c-SKI and LATS2-30UTRs were cotransfected with
miR-155 and -424 into HEK 293-T cells in the indicated combinations. (A) MiR-155 targets c-MYB. The proximal binding site is denoted Mut1, the
distal binding site is denoted Mut2, and the mutation of both binding sites is denoted Mut1+2. (B) MiR-424 targets c-MYB. The distal binding site
for is denoted Mut3, the proximal site is denoted Mut4, and the mutation of both sites is called Mut 3+4. (C) miR-424 targets SIAH1 but not
LATS2. The single miR-424-binding site in the SIAH1 30UTR was mutated and denoted SIAH1 Mut. The predicted binding site for miR-424 in the
LATS2-30-UTR was not mutated as the wt-30UTR was not responsive to miR-424. (D) miR-155 targets c-SKI. The single binding site for miR-155
was mutated and denoted SKI Mut. The values represent at least three experiments carried out in triplicate. ns: not signiﬁcant.
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for ebv-miR-BART22, -BART10 and -BART16. In
contrast to NPC samples where the EBV-encoded
miRNAs accounted for 5–19% of the total, the EBV
miRNAs represented only 1.7% of the total miRNA
counts in DLBCL. It is therefore unclear whether
EBV-miRNAs expressed at low or very low levels carry
out a function in the transformed cell.
MiRNAs from the BHRF1 cluster were reported to
repress the chemokine CXCL-11 in DLBCLs of immuno-
compromised (HIV+) patients with an EBV latency type
III (30). In contrast, the lymphomas analyzed in our
miRNA expression study were derived from immunocom-
petent patients. In accordance with the patients’ immune
status, the EBV-positive DLBCLs did not express LMP or
EBNA2 corresponding to an EBV latency type I.
Accordingly, miRNAs derived from the BHRF1-cluster
were not found as the types I and II latency do not
appear to support the expression of these transcripts.
This ﬁnding matches the situation described for NPC
(5,31), gastric carcinoma (19) and peripheral T-cell
lymphoma (32). The absence of these miRNAs was also
reported for an EBV-positive type I Burkitt’s lymphoma
(BL) cell line (3), but so far, no data were available for
primary, EBV-positive DLBCL of immunocompetent,
HIV-negative patients. The BHRF1 miRNAs might thus
play only a role in the induction of the B-cell lymphoma in
HIV-infected individuals.
EBV infection has a profound impact on cellular
miRNA expression. Both absolute levels of miRNAs
appear to be downregulated due to viral infection (33) as
well as relative levels of cellular miRNAs are also strongly
deregulated by EBV infection (5,19,31,18,34).
Nevertheless, this global downregulation of miRNAs
occurred in in vitro generated lymphoblastoid cell lines
and did not undergo a selection driven by the host
immune system during tumor formation. Recently pub-
lished data including our own had shown that miR-155
is upregulated by EBV-infection (12,34,35). MiR-155,
encoded by the BIC gene, has oncogenic potential (21).
In primary cases of BL, however, no BIC mRNA was
found regardless of the EBV status (36) while the same
group reported BIC upregulation in Hodgkin-lymphoma
and DLBCL (37). By deep-sequence analysis, we found a
relative downregulation of miR-155 in the EBV-positive
DLBCL versus EBV-negative DLBCL. In contrast, the
qRT-PCR showed an upregulation in both, EBV+ and
EBV- DLBCL as compared to reactive tonsil tissue. To
analyze the possible contribution of LMP1, we compared
by qRT-PCR the levels of miR-155 and -424 in
EBV-positive DLBCLs that were, by immunohisto-
chemistry, either LMP1-positve or LMP1-negative.
There was a trend towards upregulation in
LMP1-positive samples, but no statistically signiﬁcant dif-
ference (Supplementary Figure S2). The patient’s statistics
are shown in Supplementary Table S5. The northern blot
analysis of EBV-infected versus uninfected DLBCL
U2932 lines showed a 1.4–5.5-fold upregulation of
miR-155 in the EBV-infected cell line (which has a differ-
ent latency state than tumors) in accordance with previous
data for EBV-infected BL cell lines (12). It is thus possible
that either the differences in the miR-155 levels were due
to differences in the tissue samples employed or methodo-
logical biases may account for the observed variations.
However, we have recently shown by deep sequencing
and by qRT-PCR analysis that the sequence count
obtained by deep sequencing of small cDNA libraries
yields highly reproducible results (38). The expression of
miR-29b was lower in the EBV-positive than the -negative
cases. This miRNA was previously shown to be
upregulated by LMP1 (39); however, the lower level of
miR-29b in the EBV-positive cases analyzed in this
report might be due to the fact that our samples exhibited
a type I latency (LMP1-negative).
While all other ncRNA species stayed more or less
constant (Figure 1A and B), the proportion of miRNAs
and tRNAs changed drastically between EBV negative
and EBV positive DLBCL. In EBV-positive DLBCL, we
identiﬁed 40% less miRNAs reads compared to the
other small RNA library (Figure 1A, right panel). This
suggests that EBV might have a modulatory inﬂuence
c-MYB
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b-actin
- +  - +  - +  
a-miR-424a-miR-424
clB  cl2  
- +  
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Figure 6. (A) Induction of c-MYB and SIAH1 protein levels by anti-
sense inhibition of miR-155 and -424. Lysates of the EBV-positive
U2932 cell clones transfected with indicated antisense inhibitors to
miR-155, -424 or a scrambled oligonucleotide as a negative control
were analyzed by western blotting using anti-c-MYB or anti-SIAH1
antibody. The protein input was determined by staining for b-actin.
(B) Immunhistochemical staining for SIAH1: strong membranous posi-
tivity in a high percentage of tumor cells in an EBV- (A, left) DLBCL
versus low expression in an EBV+ DLBCL (B, right).
(C) Overexpression of miR-424 results in increased levels of
b-catenin. The EBV-positive subclones clA, clB and cl2 of the
DLBCL line U2932 or were treated with control oligonucleotide or
with pre-miR-424 for the expression of miR-424. The levels of
b-catenin and b-actin (as input control) were determined by
western-blot analysis.
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on miRNA transcription or processing pathways in vivo,
consistent with an earlier publication (33). In contrast,
the relative amount of tRNA increased roughly 2-fold
in EBV-negative to 5-fold in EBV positive DLBCL,
possibly reﬂecting a so far unknown advantageous mech-
anism of EBV to protein metabolism or an enhanced
Pol III activity (40).
MiR-424 was the miRNA that was most strongly
upregulated by EBV-infection in primary DLBCL tissue
and also the cell lines studied here, both by sequence
analysis as well as by qRT-PCR. In addition, there was
a signiﬁcant upregulation in the lymphoma samples as
compared to non-transformed tonsil tissue. The function
of miR-424 might vary depending on the cellular context
of its expression/repression. Enhanced levels of miR-424
of 5.5-fold have been reported for colon cancer (41), while
it was downregulated 2.8-fold in chronic lymphatic
leukemia (CLL) (42). In addition, miR-424 is stronger ex-
pressed in T-ALL as compared to B-ALL and may serve
as a marker to distinguish these two entities (43). MiR-424
also appears to be involved in cellular differentiation
(44,45). Interestingly, miR-424 is induced by the transcrip-
tion factor PU.1 during monocyte/macrophage differenti-
ation. PU.1 in turn is induced by EBV-infection and plays
a role in EBNA2-mediated gene expression (23).
Here, we demonstrate that miR-424 downregulates the
protein level of the ubiquitin ligase SIAH1. MiR-424 in
turn is strongly upregulated by EBV-infection in DLBCL
samples, in EBV-infected DLBCL lines and also when the
primary lymphoma tissues were compared to tonsil tissue
by qRT-PCR. SIAH1 was found to act as a tumor sup-
pressor (27,46), probably via induction of apoptosis (47)
by interference with the JNK-pathway (29,48).
Furthermore, it was shown that b-catenin levels in
Burkitt’s lymphoma lines were upregulated via
LMP1-induced down-modulation of SIAH1 (26).
Because DLBCL usually do not express the viral LMP1
oncogene, the upregulation of b-catenin via
miR-424-induced reduction of SIAH1 offers a framework
to explain the function of deregulated miR-424 in this
tumor entity. SIAH1 is a down-stream effector of p53,
and it is conceivable that induction of miR-424 prevents
p53-mediated apoptosis in the virus-infected cell.
However, miR-424 is also strongly induced in
EBV-negative DLBCL as compared to primary tonsil
tissue (Figure 3A) indicating that miR-424 plays a role
in the induction or maintenance of the DLBCL phenotype
in the absence of the virus. SIAH1 is a negative regulator
of b-catenin protein expression and we could indeed dem-
onstrate that downregulation of SIAH1 correlates with
increased b-catenin levels.
We demonstrate that c-MYB is a target of both
miR-155 and miR-424. C-MYB has oncogenic potential
(49–51) and its expression is tightly regulated during B-cell
development (52). Various miRNAs, i.e. miR-34a (53),
miR-15a (54) or miR-150 (55) regulate c-MYB protein
expression. C-MYB and miR-15a regulate each other’s
expression via a feed-back loop (56) in accordance with
a prediction that c-MYB, among other transcription
factors, regulates miRNA gene expression (57). In our
analysis, miR-15a represented 4.67% of all reads in the
EBV-negative DLBCL and 4.28% of all reads in the
EBV-positive DLBCLs indicating that expression of
c-MYB is also tightly regulated in DLBCL. The seed
sequence for miR-424 and miR-15a is the same; thus,
the increase of miR-424 might add an additional layer of
repression. The level of miR-424 rose from 0.98% in un-
infected to 1.92% of the total miRNA count in
EBV-infected DLBCL. It is unclear whether the additional
expression of both miR-155 and -424 increases the repres-
sion of c-MYB because we obtained no experimental
evidence of a cooperative effect of miR-155 and
miR-424 when the two miRNAs were co-expressed with
the c-MYB 30UTR reporter (data not shown). In
addition, miR-424 and miR-15a might compete for the
binding site(s). We have recently reported that the
myo6-30UTR is a target for both miR-145 and -143 (38).
There, we also found no cooperation of the two miRNAs
when tested together on the myo6-30UTR. So far, we have
no explanation for the observation that already the
mutation of each of the individual binding sites on the
c-MYB-30UTR results in ablated responsiveness to
miR-155. Our data imply that the two binding sites co-
operate with each other. Clariﬁcation of this problem will
require additional experiments beyond the scope of this
article.
The effect of miR-424 upregulation and the concomi-
tant downregulation of SIAH1 is inline with the role
for SIAH1 as a tumor suppressor, while the seemingly
counter-intuitive decrease in c-MYB (and possibly
c-SKI) expression might best be explained by its tightly
regulated expression during B-cell development. The effect
of miR-155 on the 30-UTR of the c-SKI proto-oncogene
could be demonstrated by luciferase assay and by
mutation of the potential binding site but not by
upregulation of c-SKI protein levels after inhibition of
miR-155. Upregulation of miR-155 in EBV-positive
DLBCL was recently shown to inhibit TGF-b1 via inhib-
ition of SmaD5 by miR-155 (58). These authors pointed
out that it was unclear how Smad3, which is also inhibited
in DLBCL was regulated in these cells as they did not ﬁnd
a direct effect of miR-155 on the SmaD3 30-UTR.
Downregulation of c-SKI might reduce its inhibitory
effect on SmaD3 which in turn activates the growth stimu-
lation by TGF- b1. Both c-SKI and c-MYB are usually
considered to be proto-oncogenes involved in transcrip-
tional activation (59,60) while their function in develop-
ment and differentiation is poorly understood. It
is possible that both c-MYB and c-SKI are involved in
differentiation, i.e. towards a promyelocytic phenotype
(61). Their expression might be incompatible with their
expression in the DLBCL setting explaining their
downregulation by miR-155. In summary, we show that
EBV infection has a profound inﬂuence on the cellular
miRNA proﬁle in DLBCL.
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